Director/PDMR Shareholding

Jun 5, 2017

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 1981H
Advanced Medical Solutions Grp PLC
05 June 2017
 


5 June 2017

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces that it was notified on 31 May 2017 that Chris Meredith, who is a Director and PDMR, following the successful achievement of certain performance criteria, had exercised the following options from certain share incentive schemes, as outlined below. Chris Meredith, also sold Ordinary Shares of 5p each on 31 May 2017 at a share price of 277.554p per Ordinary Share in part to cover the tax payable on this exercise. 

 

As a result of these transactions Chris Meredith’s beneficial interest in the Company has increased from 1,192,508 shares to 1,384,841 shares.

 

Long Term Incentive Plan (LTIP)

 

Director

No. of LTIPs prior to exercise

LTIPs exercised

Ordinary Shares sold

Ordinary shares retained

LTIPs after exercise

Chris Meredith,

Chief Executive Officer

1,078,007

445,814

271,049

174,765

632,193

 

Deferred Share Bonus Plan (DSB)

 

Director

No. of DSBs prior to exercise

DSBs exercised

Ordinary Shares sold

DSBs after exercise

Chris Meredith,

Chief Executive Officer

32,686

17,568

Nil

15,118

 

Overall holding

Director

Holding prior to exercise

Number of shares exercised

Number of shares sold

Sale price (p)

Resultant holding

% of issued share capital

Chris Meredith, Chief

Executive Officer

1,192,508

463,382

271,409

277.554p

1.384,841

0.65%

 

The Company further announces that it was notified on 31 May 2017 that Mary Tavener, who is a Director and PDMR, following the successful achievement of certain performance criteria, had exercised the following options from certain share incentive schemes, as outlined below. Mary Tavener, also sold Ordinary Shares of 5p each on 31 May 2017 as detailed below at a share price of 277.554p per Ordinary Share in part to cover the tax payable on this exercise.

 

As a result of these transactions Mary Tavener’s beneficial interest in the Company has increased from 1,829,813 shares to 1,890,647 shares.

 

Long Term Incentive Plan (LTIP)

 

Director

No. of LTIPs prior to exercise

LTIPs exercised

Ordinary Shares sold

Ordinary shares retained

LTIPs after exercise

Mary Tavener,

Chief Financial Officer

675,961

199,319

148,423

50,896

476,642

 

Deferred Share Bonus Plan (DSB)

 

Director

No. of DSBs prior to exercise

DSBs exercised

Ordinary Shares sold

DSBs after exercise

Mary Tavener,

Chief Financial Officer

19,203

9,938

Nil

9,265

 

Overall holding

Director

Holding prior to exercise

Number of shares exercised

Number of shares sold

Sale price (p)

Resultant holding

% of issued share capital

Mary Tavener, Chief

Financial Officer

1,829,813

209,257

148,423

277.554p

1,890,647

0.89%

 

The Company further announces that it was notified on 31 May 2017 that Eddie Johnson, who is a Senior Manager and PDMR, had exercised 6,243 Ordinary Shares of 5p from the Deferred Share Bonus Plan and sold 9,704 shares as detailed below at a share price of 277.554p per Ordinary Share.

 

Following these transactions the beneficial ownership of Eddie Johnson is as follows:

 

Deferred Share Bonus Plan (DSB)

 

PDMR

No. of DSBs prior to exercise

DSBs exercised

Ordinary Shares sold

DSBs after exercise

Eddie Johnson

59,237

6,243

6,243

52,994

 

Overall holding

PDMR

Holding prior to exercise

Number of shares sold

Sale price (p)

Resultant holding

% of issued share capital

Eddie Johnson

52,195

3,461

277.554p

48,734

0.023%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of 445,814 shares from the Long Term Incentive Plan

·        Exercise of 17,568 shares from the Deferred Share Bonus Plan

·        Sale of 271,049 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

£2.77554

271,049

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 271,049

Aggregated price: £2.77554

e)

Date of the transaction: 31/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Mary Tavener

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of 199,319 shares from the Long Term Incentive Plan

·        Exercise of 9,938 shares from the Deferred Share Bonus Plan

·        Sale of 148,423 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

£2.77554

148,423

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 148,423

Aggregated price: £2.77554

e)

Date of the transaction: 31/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Senior Manager/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transaction:

·        Exercise of 6.243 shares from the Deferred Share Bonus Plan

·        Sale of 9,704 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

£2.77554

9,704

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 9,704

Aggregated price: £2.77554

e)

Date of the transaction: 31/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

-End –

 

 

 

 

 

 

 

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Chief Financial Officer




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys

AMS@consilium-comms.com



Investec Bank plc(NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Daniel Adams / Patrick Robb


 

About Advanced Medical Solutions Group plc see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 600 employees.  For more information, please see www.admedsol.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

DSHBLGDLXUGBGRU

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.